Go Pro
→ Elon Warns 'America Will Go Bankrupt'. Trump's Plan Inside. (From American Hartford Gold) (Ad)tc pixel Free MRV Stock Alerts

Nuvo Pharmaceuticals (MRV) Competitors

C$44.03 +0.68 (+1.57%)
As of 10/2/2026 03:59 PM Eastern
Compare

MRV vs. VRX, APHA, BHC, MJN, and CRON

Should you buy Nuvo Pharmaceuticals stock or one of its competitors? Nuvo Pharmaceuticals's main competitors and comparable companies include Valeant Pharmaceuticals International (VRX), Aphria (APHA), Bausch Health Companies (BHC), Cronos Group (MJN), and Cronos Group (CRON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Nuvo Pharmaceuticals compare to Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International (TSE:VRX) and Nuvo Pharmaceuticals (TSE:MRV) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Nuvo Pharmaceuticals has higher revenue and earnings than Valeant Pharmaceuticals International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Valeant Pharmaceuticals InternationalN/AN/AN/AN/AN/A
Nuvo PharmaceuticalsC$8.72B4.53C$15.17MC$2.9115.13

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Valeant Pharmaceuticals International's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Valeant Pharmaceuticals International Neutral
Nuvo Pharmaceuticals Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Valeant Pharmaceuticals International's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Valeant Pharmaceuticals International's return on equity.

Company Net Margins Return on Equity Return on Assets
Valeant Pharmaceuticals InternationalN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Summary

Nuvo Pharmaceuticals beats Valeant Pharmaceuticals International on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Aphria?

Nuvo Pharmaceuticals (TSE:MRV) and Aphria (TSE:APHA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Nuvo Pharmaceuticals has higher revenue and earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B4.53C$15.17MC$2.9115.13
AphriaC$611.06M0.00-C$637.39M-C$2.01N/A

In the previous week, Nuvo Pharmaceuticals' average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Aphria Neutral

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Aphria's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Aphria N/A N/A N/A

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Nuvo Pharmaceuticals beats Aphria on 9 of the 9 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Bausch Health Companies?

Nuvo Pharmaceuticals (TSE:MRV) and Bausch Health Companies (TSE:BHC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

1.8% of Nuvo Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of Bausch Health Companies shares are held by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are held by insiders. Comparatively, 11.3% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuvo Pharmaceuticals has a beta of 0.917796, meaning that its share price is 8% less volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.707626, meaning that its share price is 29% less volatile than the broader market.

In the previous week, Bausch Health Companies had 2 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 2 mentions for Bausch Health Companies and 0 mentions for Nuvo Pharmaceuticals. Bausch Health Companies' average media sentiment score of 0.36 beat Nuvo Pharmaceuticals' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the news media.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Bausch Health Companies Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvo Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Nuvo Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B4.53C$15.17MC$2.9115.13
Bausch Health CompaniesC$10.85B0.28-C$125.65M-C$2.94N/A

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Bausch Health Companies' net margin of -12.02%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Bausch Health Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Bausch Health Companies -12.02%87.57%4.16%

Summary

Nuvo Pharmaceuticals beats Bausch Health Companies on 8 of the 14 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Cronos Group (CVE:MJN) and Nuvo Pharmaceuticals (TSE:MRV) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Nuvo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Nuvo Pharmaceuticals Neutral

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nuvo Pharmaceuticals has a net margin of 20.95% compared to Cronos Group's net margin of 0.00%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos GroupN/A N/A N/A
Nuvo Pharmaceuticals 20.95%1,180.47%5.85%

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupN/AN/AN/AN/AN/A
Nuvo PharmaceuticalsC$8.72B4.53C$15.17MC$2.9115.13

Summary

Nuvo Pharmaceuticals beats Cronos Group on 6 of the 6 factors compared between the two stocks.

How does Nuvo Pharmaceuticals compare to Cronos Group?

Nuvo Pharmaceuticals (TSE:MRV) and Cronos Group (TSE:CRON) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Nuvo Pharmaceuticals has higher revenue and earnings than Cronos Group. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo PharmaceuticalsC$8.72B4.53C$15.17MC$2.9115.13
Cronos GroupC$179.09M9.48-C$32.78MC$0.1924.26

1.8% of Nuvo Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of Cronos Group shares are owned by institutional investors. 6.3% of Nuvo Pharmaceuticals shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cronos Group had 5 more articles in the media than Nuvo Pharmaceuticals. MarketBeat recorded 5 mentions for Cronos Group and 0 mentions for Nuvo Pharmaceuticals. Nuvo Pharmaceuticals' average media sentiment score of 0.00 beat Cronos Group's score of -0.30 indicating that Nuvo Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Nuvo Pharmaceuticals Neutral
Cronos Group Neutral

Cronos Group has a consensus target price of C$4.92, suggesting a potential upside of 6.65%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Nuvo Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvo Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cronos Group has a net margin of 38.95% compared to Nuvo Pharmaceuticals' net margin of 20.95%. Nuvo Pharmaceuticals' return on equity of 1,180.47% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvo Pharmaceuticals20.95% 1,180.47% 5.85%
Cronos Group 38.95%6.46%-3.73%

Nuvo Pharmaceuticals has a beta of 0.917796, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.29991, suggesting that its share price is 30% more volatile than the broader market.

Summary

Cronos Group beats Nuvo Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Nuvo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRV vs. The Competition

Export
MetricNuvo PharmaceuticalsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$39.52BC$12.21BC$7.15BC$12.68B
Dividend Yield0.03%2.65%2.54%6.33%
P/E Ratio15.13799.70275.6739.33
Price / Sales4.53938.84656.669.16
Price / Cash0.2386.6678.8782.29
Price / Book58.7110.4610.934.61
Net IncomeC$15.17MC$2.84BC$3.51BC$299.09M
7 Day Performance3.97%-1.56%-2.00%-1.15%
1 Month Performance21.63%-5.58%-6.19%-2.92%
1 Year PerformanceN/A-2.40%8.03%16.25%

Nuvo Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRV
Nuvo Pharmaceuticals
N/AC$44.03
+1.6%		N/AN/AC$39.52BC$8.72B15.137,480
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AC$10.76BN/AN/AN/A
APHA
Aphria
N/AN/AN/AN/AC$5.24BC$611.06MN/A1,200
BHC
Bausch Health Companies
0.5861 of 5 stars		C$7.97
-0.9%		N/A-11.5%C$2.98BC$10.85BN/A20,300
MJN
Cronos Group
N/AC$12.15
-1.9%		N/A+0.0%C$1.73BN/AN/A7,600

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MRV) was last updated on 10/4/2026 by MarketBeat.com Staff.
From Our Partners
Larry's Three-Step Strategy Revealed at The Dollar Trap Summit
Larry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocu...
Brownstone Research | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
The case for $20,000 gold before year end
President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
A major gold reset could be closer than people think
For 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...
Reagan Gold Group | Sponsoredtc pixel